ONCBeiGeneFinished
Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer
Non Small Cell Lung Cancer
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.7
2 insiders sold shares within a month
Since Aug 3, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 2
- Patients
- 121 (final count)
- Started
- Mar 8, 2023
- Main results expected
- Dec 13, 2024
- Fully finished
- Jan 23, 2025
- Results posted
- Feb 9, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Major Pathological Response (MPR) Rate
Measured over: At the time of surgery, approximately Week 16
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.7, since 2026-08-03, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05577702 · record last updated 2026-02-09 · checked 2026-11-09 15:47 UTC